RecruitingPhase 4NCT06457074

Finerenone for Patients With Primary Aldosteronism (FAIRY)

Finerenone for Patients With Primary Aldosteronism (FAIRY): A Multicenter, Randomized Clinical Trial


Sponsor

Qifu Li

Enrollment

306 participants

Start Date

Jun 4, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Using spironolactone as the control, to assess the efficacy and safety of finerenone in patients with primary aldosteronism(PA).


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study (FAIRY) is testing finerenone — a drug that blocks a hormone linked to high blood pressure and fluid retention — in people with a condition called primary aldosteronism, where the adrenal glands produce too much of a blood pressure–raising hormone called aldosterone. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with primary aldosteronism, confirmed by standard blood and hormone tests **You may NOT be eligible if...** - You do not have a confirmed diagnosis of primary aldosteronism - Your diagnosis does not meet the required lab thresholds - You have other conditions that would make this medication unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFinerenone Oral Tablet

Eligible patients will be started finerenone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).

DRUGSpironolactone Oral Tablet

Eligible patients will be started spironolactone at 20mg per day, Dose will be adjusted every four weeks to achieve the targeted blood pressure (the mean office blood pressure \<140/90 mmHg).


Locations(1)

the first affiliated hospital of Chongqing medical university

Chongqing, Chongqing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06457074


Related Trials